<DOC>
	<DOCNO>NCT00512070</DOCNO>
	<brief_summary>Atypical antipsychotic medication , olanzapine , cause metabolic side effect , include weight gain , extra fat around middle body , high blood sugar , high cholesterol . One mechanisms medication may cause effect reduce plasma melatonin . This study pilot project evaluate 1 ) effect olanzapine melatonin secretion level 2 ) effect melatonin olanzapine-induced change melatonin secretion patient schizophrenia , schizoaffective , bipolar disorder .</brief_summary>
	<brief_title>Melatonin Metabolism Abnormality Patients With Schizophrenia Schizoaffective Disorder Treated With Olanzapine</brief_title>
	<detailed_description>To investigate relationship olanzapine , melatonin , metabolic functioning , pilot study evaluate 20 patient schizophrenia , schizoaffective disorder , bipolar disorder 15 week three experimental condition : 1 ) baseline ( two week treatment already establish antipsychotic medication olanzapine clozapine ) , 2 ) six week treatment olanzapine , 3 ) six week treatment olanzapine melatonin . Half patient receive 0.3 mg oral melatonin half receive 3.0 mg melatonin . Nocturnal melatonin production , estimate assay urinary 6-sulfatoxymelatonin ( aMT6s ) adjust creatinine , measure weekly . In addition , weekly measurement weight metabolic index , include waist hip measurement , fast glucose , serum insulin , cholesterol , triglyceride , leptin take . It anticipate olanzapine-induced decrease melatonin production . Furthermore , expect decrease melatonin production associate olanzapine treatment reverse administration melatonin olanzapine .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Age 1865 ; 2 . DSMIVTR diagnosis schizophrenia , schizoaffective disorder , bipolar disorder ; 3 . Patients , clinical judgment investigator , may benefit switch olanzapine ; 4 . Females must nonchild bear potential ( i.e. , surgically sterilize , least one year postmenopausal ) appropriate dose oral/depot contraceptive use barrier protection breastfeeding . Females must urine pregnancy test screening ; 5 . Willingness ability take medication nightly 10:00 p.m. ; 6 . The subject his/her legal representative must provide informed , write consent . 1 . Females pregnant lactating ; 2 . Concurrent participation participation within prior 30 day study involve investigational medication ; 3 . Current ( within prior 30 day ) diagnosis substance abuse dependence ; 4 . Use olanzapine within prior three month ; 5 . History allergy intolerable sideeffects olanzapine past ; 6 . History significant head trauma , define head trauma result loss consciousness five minute and/or neurological cognitive sequela ; 7 . Evidence clinically relevant disease ( e.g. , renal hepatic impairment , significant coronary artery disease , cerebrovascular disease , cancer ) clinical find opinion investigator could potentially negatively affected study participation could potentially affect study participation criterion exclusion study ; 8 . Use fluvoxamine , nifedipine , warfarin 30 day prior Baseline Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>olanzapine</keyword>
	<keyword>melatonin</keyword>
	<keyword>obesity</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>